# Ipamorelin FAQ: Direct Answers from the Published Record > Ipamorelin FAQ — direct, cited answers on what it does, IGF-1, muscle, risks, the CJC-1295 combination, half-life, and FDA status, drawn straight from the published research. Not medical advice. Direct answers, cited where the claim is quantitative — on what ipamorelin does, what it doesn't, and where the human evidence runs out. ## What does ipamorelin do for you? Ipamorelin releases a pulse of growth hormone by activating the ghrelin receptor (GHS-R1a) on the pituitary. Its distinctive trait is doing so cleanly: in its founding characterization it released growth hormone potently in rat pituitary cells, rats, and swine (swine ED50 2.3 nmol/kg) without raising cortisol [1]. What that translates to for any individual has not been established in controlled human outcome trials. ## Does ipamorelin increase IGF-1? Sometimes, but not reliably in short studies. Growth hormone normally drives the liver to make IGF-1, yet in a 15-day rat bone-growth study, dose-dependent skeletal effects occurred with no measurable change in total IGF-1 [4]. CJC-1295, the GHRH analog often paired with ipamorelin, produces more durable IGF-1 elevation [7]. So IGF-1 response depends on the protocol and the timeframe. ## What does ipamorelin peptide do? The ipamorelin peptide (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) tells the pituitary to release a single growth-hormone pulse by mimicking ghrelin at the GHS-R1a receptor [1]. It is the selectivity that defines it — strong growth-hormone release without the cortisol and prolactin bump seen with older GHRPs [1]. Beyond that pulse, its broader effects in people remain largely uncharacterized in controlled trials. ## Does ipamorelin build muscle? No controlled human trial has shown ipamorelin builds muscle. The supporting evidence is preclinical and indirect: the ipamorelin-derived oral analog NN703 produced body-weight gain in rats over 14 days [10], and a 2026 review reported the CJC-1295 + ipamorelin combination improved muscle tetanic tension in a mouse muscle-loss model [14]. Reported lean-mass changes in community use are anecdotal and confounded by diet and training. ## What is ipamorelin? Ipamorelin is a synthetic pentapeptide — a five-amino-acid chain — and the first highly selective growth hormone secretagogue, characterized in 1998 [1]. It activates the ghrelin/GHS-R1a receptor to release growth hormone without meaningfully raising ACTH, cortisol, or prolactin [1]. Developed by Novo Nordisk as NNC 26-0161, it was later trialed for postoperative ileus and never approved as a drug. ## What is ipamorelin peptide? Ipamorelin peptide is a wholly synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective ghrelin-receptor agonist, releasing a growth-hormone pulse [1]. It is not an endogenous human peptide — it mimics ghrelin's action at GHS-R1a. Its non-natural Aib residue at position 1 increases resistance to enzymatic breakdown, which is part of why it is more stable than some earlier GHRPs. ## What are the risks of ipamorelin? The documented risks are mostly unknowns. The one human efficacy trial (NCT00672074, n=114) found no ipamorelin-specific safety signal over 7 days but also missed its endpoint [3]. The larger concerns are long-term and class-level: a 28-day study of a related GHS-R1a agonist found heart-muscle damage in rats [6], and GH-axis stimulation raises theoretical IGF-1/cancer questions [4]. Long-term human safety is uncharacterized. ## Does ipamorelin reduce belly fat? No human trial has tested ipamorelin for belly fat. The relevant animal data are about weight defense, not fat loss: a 2024 ferret study found intraperitoneal ipamorelin (1–3 mg/kg) inhibited cisplatin-induced body-weight loss by about 24% during the delayed phase [5]. Community reports of a gradually leaner look are anecdotal and confounded by concurrent diet and training [4]. ## What are the downsides of ipamorelin? The biggest downside is the evidence gap: one human efficacy trial, and it failed [3]. Beyond that, community-reported nuisances include post-injection facial flushing, mild water retention, tingling, increased appetite, and a fading response over months — all anecdotal. The class-level cardiac signal from a related agonist [6] and the absence of long-term human safety data are the substantive concerns. ## Why is ipamorelin being discontinued? Ipamorelin was never an approved product to discontinue, but its clinical development effectively stopped because its only Phase 2 trial failed: in postoperative ileus (NCT00672074, n=114), it missed its primary endpoint (25.3 h vs 32.6 h to first tolerated meal, p=0.15) [3]. Separately, in 2024 the FDA narrowed compounding-pharmacy access by removing ipamorelin acetate from the interim 503A Category 2 list. ## What does CJC-1295 and ipamorelin do? Together they aim to raise growth hormone through two doors at once: ipamorelin fires a ghrelin-receptor pulse [1], while CJC-1295, a long-acting GHRH analog, sustains the GH/IGF-1 axis with more durable IGF-1 elevation [7]. The pairing logic is complementary mechanisms. There is no controlled human trial of the combination for any outcome — only single-agent pharmacology. ## How does CJC-1295 ipamorelin work? The combination works by hitting two different receptors. Ipamorelin activates the ghrelin/GHS-R1a receptor to trigger a discrete growth-hormone pulse [1]; CJC-1295 activates the GHRH receptor to raise baseline GH/IGF-1 axis tone [7]. Because the pathways are distinct and complementary, the growth-hormone-releasing effects can add together — which is the rationale behind pairing a short-acting GHRP with a long-acting GHRH analog. ## How much CJC-1295 ipamorelin should I take? No published source supports a human dose, and this site does not provide one. Community subcutaneous 'stack' protocols have no peer-reviewed human dosing basis, and the combination itself has never been tested in a controlled human trial [7]. The only solid dosing-adjacent figures are single-agent pharmacokinetics — ipamorelin's ~2-hour half-life and 40-minute pulse [2]. Anyone facing a real decision should consult a qualified professional. ## Does CJC-1295 ipamorelin work? Each peptide works pharmacologically — ipamorelin releases a growth-hormone pulse [1] and CJC-1295 raises IGF-1 [7] — but the combination's marketed outcomes have not been demonstrated in any controlled human trial. The nearest evidence is a preclinical muscle-tension improvement in a mouse model reported in a 2026 review [14]. Pharmacologically active; clinically unproven for the combination. ## How to reconstitute CJC-1295 ipamorelin 5mg? Ipamorelin is supplied as a lyophilized (freeze-dried) powder and, in research handling, reconstituted with bacteriostatic water; as a peptide it degrades with heat and freeze-thaw and is generally refrigerated [2]. These are general research-supply handling notes, not a clinical preparation instruction. No validated human-use reconstitution protocol exists for a combination product, because no such product is approved. ## How long does ipamorelin stay in your system? Ipamorelin clears quickly. In healthy human volunteers, its terminal half-life is about 2 hours (IV), with clearance of 0.078 L/h/kg, and the growth-hormone response peaks near 40 minutes as a single pulse [2]. Practically, the parent peptide is largely gone within several hours, though the downstream growth-hormone pulse it triggers plays out on its own timeline. ## Does ipamorelin make you hungry? It can, because it acts on the ghrelin (hunger) receptor. Community reports describe increased appetite in the hours after injection, generally milder than with GHRP-6, though anecdotal [9]. Mechanistically this fits: ghrelin-receptor agonism is tied to appetite, and ipamorelin's growth-hormone selectivity does not remove the receptor-level orexigenic signal. ## Will I gain weight on ipamorelin? There is no human trial answering this. Preclinically, the ipamorelin-derived analog NN703 caused body-weight gain in rats over 14 days [10], and the parent compound's ghrelin-receptor action can increase appetite [9]. Community accounts vary between leaner body composition and fluid-related puffiness — all anecdotal and confounded. The single 7-day human trial did not report weight gain as a signal [3]. ## Does ipamorelin increase appetite? Yes, increased appetite is a class-level effect of ghrelin-receptor agonists, and ipamorelin is one. In diabetic mice, ipamorelin produced strong growth-hormone hypersecretion [9], and the receptor it uses governs hunger signaling. Community users report an appetite uptick after dosing, described as milder than GHRP-6 but real for some — anecdotal, not a controlled finding. ## How long does it take for ipamorelin to work? Pharmacologically, fast: the growth-hormone pulse peaks near 40 minutes after a dose in human PK studies [2]. For the subjective effects people chase — sleep, recovery — community reports describe onset within one to two weeks, but those are anecdotal and unverified. The acute hormone response and the perceived longer-term effects are on very different timescales. ## Does ipamorelin cause water retention? Some community users report mild, transient water retention — puffiness in fingers, ankles, or face — usually in the first two to four weeks and often described as milder than with older GHRPs; this is anecdotal [3]. Mechanistically, growth-hormone elevation is associated with sodium and water retention, which makes the reports plausible, though no controlled ipamorelin study has quantified it. ## Where to inject CJC-1295 ipamorelin? This site does not give injection instructions. For reference only: in the research literature, subcutaneous administration was the dominant route in rodent body-composition studies and in community use [4], while human trials used intravenous infusion [2]. Describing where studies administered a compound is not a directive to inject anything; no approved combination product or human-use protocol exists. --- A star-chart reading of the ipamorelin record — the bright confirmed points (the 1998 selectivity, the ~2-hour human half-life) charted apart from the faint speculative ones, and the regulatory status read straight from the register; no clinic behind the atlas and nothing here dosed, compounded, prescribed, or sold.